Matthew B. Klein

Matthew B. Klein

DirectoratPTC Therapeutics· In proxies 2022–2025

Pay in FY2024-17% from the year before · PTC Therapeutics stock +63.8% the same year

Matthew B. Klein was paid $7.4M in FY2024 (Dec), down 17%. PTC Therapeutics stock rose 63.8% that year.

Pay$100 in the stock at the end of FY21 → $113
Pay is from the Summary Compensation Table of each PTC Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. ClearPoint NeuroPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. PTC TherapeuticsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role +54%
  3. ClearPoint Neuro, Inc.Public company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  4. PTC Therapeutics International Holdings Unlimited CompanyPublic company
    • Director? – PresentNo stock prices for these years
  5. PTC Therapeutics International LimitedPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?